FDA
-
-
-
-
-
-
-
TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma
-
-
-
-
-
-
-
TCR² Therapeutics Hires Key Business Development and Regulatory Affairs Cell Therapy Experts to Support Strategic Objectives
-
-
-
-
-
-
-
TCR2 Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

